#HealthCareindustry

From CNBC: CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

For some experts, the outbreak is raising broader concerns about how equipped the U.S. is to respond to future infectious disease threats.

Makary's tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines.

Remote expedition cruises to destinations like Antarctica and the Arctic are booming, but the deadly hantavirus aboard MV Hondius is a reminder of unique risks.

Whoop is introducing on-demand clinician access and AI-powered health guidance, largely included in the price of membership.

New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.

Shares of Planet Fitness plunged Thursday after the fitness company slashed its guidance and canceled planned price hikes.

From Google News - World: Family office deal-making rebounds in April with healthcare bets - CNBC

Healthcare startups made up nearly a third of April's investments by family offices.

From Google News - World: Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals - CNBC

Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.

All of the health-care giant's business segments, including its insurer Aetna, its retail pharmacy and health services unit, surpassed expectations.

Supplement patch company Barrière is launching the first-ever lactose intolerance patch in 1,700 Walmart stores, the company told CNBC exclusively.

The studies were "withdrawn because the authors drew broad conclusions that were not supported by the underlying data," the spokesperson told CNBC.

U.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David Faber.

From CNBC: Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth